These experiments were conducted to determine whether point mutations activating K-ras or H-ras oncogenes, induced by the procarcinogen 1,2-dimethylhydrazine (DMH), were detectable in preneoplastic or neoplastic rat colonic mucosa. Rats were injected weekly with diluent or DMH at 20 mg/kg body wt for 5, 10, 15, or 25 wk, killed, and their colons dissected. DNA was extracted from diluent-injected control animals, histologically normal colonic mucosa from carcinogen-treated animals, and from carcinomas. Ras mutations were characterized by differential hybridization using allele-specific oligonucleotide probes to polymerase chain reaction-amplified DNA, and confirmed by DNA sequencing. While no H-ras mutations were detectable in any group, K-ras (G to A) mutations were found in 66% of DMH-induced colon carcinomas. These mutations were at the second nucleotide of codons 12 or 13 or the first nucleotide of codon 59 of the K-ras gene. The same type of K-ras mutations were observed in premalignant colonic mucosa from 2 out of 11 rats as early as 15 wk after beginning carcinogen injections when no dysplasia, adenomas, or carcinomas were histologically evident, suggesting that ras mutation may be an early event in colon carcinogenesis. (J. Clin. Invest. 1991. 87:624-630.)
Introduction
Colonic carcinogenesis appears to be a complex phenomenon, which proceeds through multiple stages, including initiation, promotion, and progression (1) . Increasing evidence suggests that this multistage process may result from the accumulation ofgenetic alterations in certain protooncogenes or other genes, thereby leading to progressive disordering of the mechanisms that normally regulate cellular growth and differentiation (2) . Sites of genetic alteration implicated in the development of human colonic neoplasia include the adenomatous polyposis coli locus on chromosome 5, the p53 gene on chromosome 17 , and the "deleted in colorectal cancer" gene on chromosome 18 (3) . Another genetic alteration suggested to be ofimportance in the pathogenesis of colonic malignant transformation is ras gene mutation (4, 5) . H-ras, K-ras, or N-ras genes encode similar 21,000-D membrane-bound proteins with intrinsic GTPase activity that have a presumptive role in growth signal transduction (6) . Single point mutations at specific sites within ras genes activate their oncogenic potential and such mutations have been observed in many human tumors (7) , including human colon carcinomas. K-ras mutations, for example, have been reported in -40-50% ofthese latter malignancies (3) (4) (5) . Moreover, such mutations have also been detected in premalignant adenomas as well as in "normal" colonic mucosa adjacent to carcinomas, suggesting that these genetic alterations may be an early event in tumorigenesis of this organ (8) .
In this regard, in recent years experimental models ofcarcinogenesis have been used to search for and elucidate the molecular mechanisms, such as ras protooncogene activation, involved in these multistage processes for many malignancies other than colon cancer (9) . For example, experiments with the alkylating agent N-nitroso-N-methylurea have demonstrated that mammary carcinomas induced by this agent have G to A mutations at one specific site, the second nucleotide of codon 12 of the H-ras oncogene (10) . These findings are of interest since this carcinogen generates the methylated adduct 06_ methylguanine which, ifnot repaired, may mispair with thymidine during DNA replication resulting in a G:C to A:T transition (1 1). Taken together, these results, therefore, strongly suggest a causal relationship between N-nitroso-N-methylurea administration, H-ras mutation, and the initiation of carcinogenesis. Moreover, the selective nature ofthese mutations may be related to site-specific differences in accessibility of the carcinogen to DNA, or alternatively to differential rates of formation and/or repair of these adducts, in addition to possible selection for particular amino acid substitutions in the ras protein (12, 13 ( 14, 15) . Colon carcinomas appear after a latency period of -6 mo in almost all rats injected with the usual dosage schedule of DMH, if the rats are from a susceptible strain (16) . These tu-mors closely parallel human colonic neoplasia in clinical and pathologic features (15) (16) (17) (18) ). An initial indication that the Kras oncogene may be activated by DMH in these tumors was previously obtained by Caignard and colleagues using the NIH/3T3 transformation assay (19) ; however, these investigators did not determine whether these mutations are frequent events and did not characterize any specific point mutations. The spectrum of mutations (site and type of nucleotide substitution) is important because it may provide evidence for particular mechanisms of mutagenesis (13) . In these experiments we, therefore, investigated the pattern of mutations induced in the H-ras or K-ras oncogenes by 1,2-dimethylhydrazine in rat colon carcinomas and premalignant carcinogen-treated colonic mucosa, to provide information regarding the mechanism of activation of the ras oncogene by this carcinogen, and to determine whether these mutations are an early event in colon carcinogenesis. The results of these studies as well as a discussion of their relevance to colonic malignant transformation in this model serve as the basis for this report.
Methods
Materials. Thermus aquaticus (Taq) DNA 25 wk. The stock solution for injections consisted of DMH dissolved in 100 ml water containing 37 mg EDTA and was adjusted to pH 6.5 with sodium hydroxide. The animals were maintained on a pelleted diet (Purina rat chow from Ralston-Purina Co., St. Louis, MO) with water and food ad lib. in standard cages. I wk after the last DMH injection, the animals were killed by halothane inhalation and their colons excised. Gross tumors were identified, their size and location in millimeters from the anus were recorded, and the tumors were carefully dissected from each colon. Tissue specimens -1-2 mm2 in area were taken from control colonic mucosa, from normal preneoplastic colons after 5, 10, or 15 wk of carcinogen treatment, and from carcinomas or "uninvolved" proximal and distal colon after 26 wk of DMH treatment, and were frozen quickly in liquid nitrogen for subsequent DNA extraction. Portions ofthese specimens were also preserved in formalin for histopathologic examination as previously described (20) .
Oligonucleotide synthesis and preparation. Oligonucleotides, for use as "amplimers" or probes, were synthesized on a 380B synthesizer (Applied Biosystems, Inc., Foster City, CA) for rat K-ras (Table I) and rat H-ras (Table II) 5'GTT GGA GCT GGT GGC GTAGG3' GTT GGA GCT TGT GGC GTA GG GTT GGA GCT AGT GGC GTA GG GTT GGA GCT CGT GGC0GTA GG GTT GGA GCT GTT GGC GTA GG GTT GGA GCT GAT GGC0GTA GG GTT GGA GCT GCT GGC0GTA GG GTT GGA GCT GGT GGC0GTA GG GTT GGA GCT GGT TGC GTA GG GTT GGA GCT GGT AGC GTA GG GTT GGA GCT GGT CGC GTA GG GTT GGA GCT GGT GTC GTA GG GTT GGA GCT GGT GAC GTA GG GTT GGA GCT GGT GCC GTA GG GAC ACA GCA GGT CAA GAC ACA TCA GGT CAA GAC ACA CCA GGT CAA GAC ACA ACA GGT CAA GAC ACA GGA GGT CAA GAC ACA GTA GGT CAA GAC ACA GAA GGT CAA 42-440C for the 1 5-mer probes). A sample was designated as containing a mutated ras sequence only if autoradiograms showed significant mutant probe binding to that amplified DNA after increasing the final wash temperature close to the melting temperature for that probe. Filters were autoradiographed using intensifier screens and Kodak XAR-5 film at -70'C for 1-16 h. DNA sequencing. Mutations were confirmed by direct sequencing of amplified DNAs using the dideoxynucleotide chain termination method (27) . PCR-amplified DNA was purified on anion-exchange columns, extracted with isopropranol, and resuspended with a 32P-labeled antisense primer (5' TCGTAGGATCATATTCATCC 3') in 10j1A of40 mM Tris, 20 mM MgCl2, 50 mM NaCl, pH 7.5. The primer-template mixture was denatured for 3 min at 90°C, annealed at 55°C for 15 min; then I ,ul of 0.1 M dithiothreitol and I gl of a manganese buffer were added, before the addition of 2 U of Sequenase enzyme (28, 29) .
After transferring 3 ,l to each of four termination mixes, the solutions were incubated at 37°C for 3 min, electrophoresed on an 8% polyacrylamide-urea gel, and then autoradiographed.
Results
Specific K-ras oncogene G to A mutations arefound in DMHinduced rat colon carcinomas. The spectrum of mutations induced by DMH had not previously been determined, therefore, we analyzed colon carcinoma DNAs to find which specific nucleotide substitutions were induced in ras genes by this carcinogen. 44 carcinomas and 20 histologically normal colonic mucosal specimens were obtained from 37 rats treated with carcinogen for 26 wk, and DNA was extracted from each. After PCR amplification of the relevant regions of exon 1 80  75  85  150  60  80  150  60  65  80  100  80  60  70  85  70  50  65  65  165  30  70  90  80  10  115  195  160  20  85  170  60  30  40  15  80  60  70  15  85  25  30  40  75 Codon 12
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* Tumor size in square millimeters of mucosal area involved. * Tumor location in millimeters from the anus. * Dashes in the first, second, or third nucleotide positions indicate normal wild type sequence at those sites for codon 12 (GGT), codon 13 (GGC), or codon 59 (GCA). Mutations, which were all G to A transitions, are indicated by an A at the mutated site.
after 15 wk of carcinogen treatment, a finding confirmed by DNA sequencing (Fig. 3) . The mutations found, codon 12 GGT to GAT in both cases, are the same type as seen in the majority of carcinomas after 26 wk of DMH treatment.
K-ras mutation rate correlates with tumor size. The location of each colon tumor (distance in millimeters from the anus) and tumor size (mucosal area in square millimeters) were recorded at the time of killing of each rat, and these data are related to the type ofK-ras mutation in Table IV . The majority of carcinomas in this rat strain are located in the distal colon, comparable to the distribution of sporadic colon cancers in humans (16) . Distal colon carcinomas (0-100 mm from anus) had a K-ras mutation rate of 70%, in contrast to only 43% in proximal colon carcinomas; however, these differences did not reach statistical significance (P > 0.05).
The presence of ras mutations might be expected to increase tumor growth rate (7) and therefore correlate with larger tumor size, but our results show the opposite. Tumors without ras mutation were larger, 42±17 mm2 (n = 15) vs. 20.4±3.8 mm2 (n = 29) for tumors with mutated K-ras sequences (P < 0.05). All tumors > 100 mm2 in area lacked ras mutation (P < 0.05 by chi-square analysis).
Tumors from rats with multiple carcinomas had a higher incidence of ras mutation with 76% of the tumors mutated if three or more tumors were present, 57% mutated iftwo tumors were present, and 25% mutated ifthere was only one tumor per rat. Nine rats had multiple tumors with different K-ras sequences in tumors from the same rat, indicating that the ras mutations occurred as independent events.
Discussion
These experiments demonstrate for the first time that approximately two-thirds of DMH-induced colonic tumors have detectable K-ras mutations, and these are all G to A transitions. Moreover, similar mutations were also detected in the preneoplastic colonic tissue of animals treated with this carcinogen, albeit at a lower rate.
While it therefore appears that both sporadic human cancers and DMH-induced tumors have a high incidence of K-ras mutations, it should be noted that the K-ras mutations seen in colonic malignancies in this model differ from their human counterparts in several respects. Thus, the DMH-induced colonic mutations were exclusively G to A transitions, while sporadic human colonic tumor K-ras mutations exhibit A, T, or C substitutions at either the first or second nucleotides of K-ras codon 12 (3-5, 7, 8) . There was an interesting positional bias in DMH mutations with the second nucleotide of codon 12 mutated two and one-half times as often as the second nucleotide ofcodon 13, and codon 59 mutations occurring rarely. Although G to A mutations of the first nucleotide of codon 12 are frequent in sporadic human colon cancers (3-5, 7, 8) (5) . Although these earlier studies implied that ras mutations may occur early in the formation of adenomas, the occurrence of these mutations in preneoplastic colonic mucosa has not previously been described. We detected K-ras mutations, ofthe same type as later found in carcinomas, in histopathologically normal colonic mucosa after only 15 Finally, as noted earlier, animal models, such as the one used in these studies, have distinct advantages including: (a) preneoplastic tissue can be obtained; (b) tumors develop as a relatively synchronized cohort; and (c) factors possibly influencing genetic alterations and malignant progression can be manipulated and controlled. Future studies, using the DMH model to explore the possible relationship between other genetic alterations and their role in colonic malignant transformation, will, therefore, be of interest and are currently being conducted in our laboratory.
